Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary—Clinical significance of BRCA2 gene variants in genomically stable tumors

• Published in: Gynecologic oncology Vol. 161; no. 3; pp. 762 - 768
• Main Authors: Zhang, Xiaoming, Devins, Kyle, Ko, Emily M., Reyes, Maria Carolina, Simpkins, Fiona, Drapkin, Ronny, Schwartz, Lauren E., Yoon, Ju-Yoon
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2021
• Subjects: Adolescent; Adult; Aged; BRCA2; BRCA2 Protein - genetics; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - mortality; Cystadenocarcinoma, Serous - pathology; Female; Genetic Predisposition to Disease; Homologous recombination pathway; Humans; Low-grade serous ovarian carcinoma; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Ovarian Neoplasms - genetics; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; PARP inhibitor; Pennsylvania; Serous borderline tumor; Young Adult; Pennsylvania; Homologous recombination pathway; Serous borderline tumor; BRCA2; Low-grade serous ovarian carcinoma; PARP inhibitor

The mutational spectra of low-grade serous carcinomas (LGSCs) and serous borderline tumors (SBTs) of the ovary are poorly characterized. We present 17 cases of advanced or recurrent LGSC/SBT patients who underwent molecular profiling. Thirteen LGSCs and four SBTs underwent targeted gene panel testin...